The World Health Organization (WHO) has released a draft guideline endorsing the use of anti-obesity medications such as Wegovy (semaglutide) for adults with BMI ≥30, or BMI ≥27 with comorbidities (e.g., hypertension, type 2 diabetes). The draft—open for public comment until 27 September—frames obesity as a chronic, relapsing disease and embeds pharmacotherapy within a multimodal model of care alongside lifestyle and behavioral interventions.
On September 5, WHO updated the Essential Medicines Lists (EML) to expand access to GLP-1 agents for type 2 diabetes, but it did not list GLP-1 drugs specifically for obesity treatment—reflecting concerns about cost and equitable access. Thus, the new obesity guideline promotes combination care, while the EML remains diabetes-focused for now.
For the public, the familiar names are Wegovy, Ozempic, and Saxenda—all GLP-1 receptor agonists. They enhance satiety and slow gastric emptying, thereby reducing food intake. Wegovy is a once-weekly injection with widely cited trials showing >15% average weight loss versus placebo. Ozempic shares the same active ingredient (semaglutide) but is approved for type 2 diabetes; it is often used to assist weight management in practice. Saxenda (liraglutide), a once-daily injection, demonstrated a significantly higher proportion of patients achieving ≥5% weight loss in randomized trials (e.g., SCALE).
Safety deserves careful attention. Prescribing information for semaglutide products (Wegovy/Ozempic) carries a boxed warning for thyroid C-cell tumors observed in rodents, with contraindication in patients with MTC or MEN2. Labels also warn about pancreatitis, gallbladder disease, acute kidney injury (often with dehydration), gastrointestinal hypomotility/ileus, and hypoglycemia when combined with insulin or sulfonylureas. Worsening of diabetic retinopathy has been reported; people with pre-existing retinopathy should be monitored. Nausea, vomiting, and abdominal pain are the most common side effects and are often mitigated by slow dose escalation and dietary adjustments.
Regarding suicidality signals, the EMA’s PRAC concluded in 2024 that available evidence does not support a causal association with GLP-1 RAs, though vigilance in vulnerable patients remains prudent.
In South Korea, Wegovy prescriptions have surged, but the drug is generally not reimbursed by national insurance for obesity. Regulatory and payer bodies have signaled a cautious stance, and as of early September, no formal reimbursement application for Wegovy had been filed with HIRA. Patients should therefore plan for out-of-pocket costs and discuss long-term treatment strategies with clinicians.
These medicines are tools, not cures. Outcomes improve when pharmacotherapy, lifestyle change, and behavioral counseling move together, under regular clinical monitoring (glucose, lipids, renal/hepatic function, gallbladder, and eye health when indicated). WHO’s draft underscores multidisciplinary care and equity of access, while patients should focus on health outcomes that matter—cardiometabolic risk reduction, not just the number on the scale.
In short, two truths stand out. First, obesity is a disease that merits medical management—not a personal failure. Second, drugs like Wegovy, Ozempic, and Saxenda can open doors, but daily habits decide how far we walk through them. Health is shaped by what we repeat; medications can point the way, and our routines carry us there.